An Italian firm has published promising results from its phase-two clinical trials, in which its Covid-19 vaccine induced an antibody response in 93% of volunteers three weeks after the first dose, reaching 99% after the second. … Read More >Italian Covid-19 vaccine demonstrates safety and efficacy in phase-2 trial